Table 1 Correlation between SH3RF2 expression levels and clinicopathological parameters of OC patients.

From: SH3RF2 contributes to cisplatin resistance in ovarian cancer cells by promoting RBPMS degradation

Clinical parameters

Cases

SH3RF2 expression levels

p value

High

Low

Overall

120

61

59

 

Age

   

0.2031a

 ≤55

62

35

27

 

 >55

58

26

32

 

FIGO stage

   

0.2716a

 I-II

18

7

11

 

 III-IV

102

54

48

 

Tumor size

   

<0.05a

 ≤7 cm

66

28

38

 

 >7 cm

54

33

21

 

Metastasis

   

0.3029a

 Positive

98

52

46

 

 Negative

22

9

13

 

Grading

   

0.4561b

 High-grade

111

58

53

 

 Low-grade

9

3

6

 

Subtype

   

0.8269a

 Serous

98

51

47

 

 Mucinous

6

3

3

 

 Others

16

7

9

 

DDP-based chemotherapy

   

<0.0001a

 DDP resistant

61

46

15

 

 DDP sensitive

59

15

44

 
  1. aChi-square test.
  2. bChi-square test with Yates’ correction.